Abbott Buying Evalve for Up To $410 Million
Abbott (NYSE: ABT) has agreed to acquire Evalve Inc., a Menlo Park, Calif.-based provider of devices for minimally invasive repair of cardiac mitral valves. The deal includes a $320 million up-front payment, plus another $90 million in possible earnouts. Evalve has raised over $100 million in VC funding from firms like ABS Ventures, Abbott Labs, Delphi Ventures, New Enterprise Associates and Split Rock Partners.
11 September 2009•3 mins read
